CytoSorbents executives take salary reduction; CEO by 35%, others by 15%

Cytosorbents Corp

CEO Phillip Chan reduces salary by 35% ($123,498) to $359,353 through Dec 31, 2024.
CFO Kathleen Bloch reduces salary by 15% ($46,587) to $378,413; same for other NEOs.
Board grants nonqualified stock options equal in value to each reduction at $0.95/share.
Options vest fully on Jan 31, 2025; expired 10 years from grant date.
Program aims to cut costs; salaries automatically restore to prior level after 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.